liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Galantamine demonstrates efficacy and safety in elderly patients with Alzheimer disease
Linköping University, Faculty of Health Sciences. Linköping University, Department of Neuroscience and Locomotion, Geriatrics. Östergötlands Läns Landsting, MC - Medicincentrum, Geriatrik-LAH.
Show others and affiliations
2003 (English)In: Alzheimer Disease and Associated Disorders, ISSN 0893-0341, Vol. 17, no SUPPL. 3Article in journal (Refereed) Published
Abstract [en]

Alzheimer disease (AD) treatment guidelines state that cholinergic agents are not cost-effective in patients with more severe disease. Because many physicians may deem an older patient unlikely to respond to treatment, older AD patients may remain untreated. Galantamine (Reminyl), a novel cholinergic agent, is effective in mild to moderate AD. This post hoc analysis of pooled phase III galantamine clinical trials was designed to assess whether older (=80 years) and younger (=79 years) AD patients experience similar benefits with galantamine based on changes in the ADAS-cog and CIBIC-plus. Mean ADAS-cog scores for older patients treated with galantamine 24 mg/day significantly improved versus baseline and versus placebo at month 3. Cognitive improvement was maintained versus placebo at month 6, the ADAS-cog score for placebo patients dropped below baseline at month 6. Change in CIBIC-plus for galantamine was significantly different from placebo at months 5 to 6. Mean ADAS-cog score in older patients taking galantamine for 12 months remained above baseline. The score for patients taking placebo for 6 months before switching to galantamine did not differ significantly from baseline at 12 months but was lower than in patients receiving galantamine for 12 months. Incidence of adverse events in patients > 80 years was similar to that in the overall study population. Galantamine maintained cognitive and global function in patients > 80 years with mild to moderate AD for at least 5 to 6 months and cognitive efficacy for 12 months. Prescribing approved therapies such as galantamine for older patients with AD is recommended.

Place, publisher, year, edition, pages
2003. Vol. 17, no SUPPL. 3
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-27880DOI: 10.1097/00002093-200307003-00005Local ID: 12640OAI: diva2:248432
Available from: 2009-10-08 Created: 2009-10-08 Last updated: 2011-01-13

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Marcusson, Jan
By organisation
Faculty of Health SciencesGeriatricsGeriatrik-LAH
In the same journal
Alzheimer Disease and Associated Disorders
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 15 hits
ReferencesLink to record
Permanent link

Direct link